Cytomegalovirus infection in transplant recipients: Newly approved additions to our armamentarium
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytomegalovirus infection in transplant recipients: Newly approved additions to our armamentarium
Authors
Keywords
-
Journal
CLINICAL MICROBIOLOGY AND INFECTION
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-07-15
DOI
10.1016/j.cmi.2022.07.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Letermovir Primary Cytomegalovirus Prophylaxis on 1-Year Mortality After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort Study
- (2022) Yiqi Su et al. CLINICAL INFECTIOUS DISEASES
- Letermovir and maribavir for pan‐resistant cytomegalovirus infection in a patient with haematologic malignancy: Consideration for combination therapy
- (2022) Jana K. Dickter et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation
- (2021) Danniel Zamora et al. BLOOD
- Refractory and Resistant Cytomegalovirus after Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era
- (2021) Joseph Sassine et al. CLINICAL INFECTIOUS DISEASES
- Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients
- (2021) Wieteke Kleinherenbrink et al. PHARMACOLOGICAL RESEARCH
- Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
- (2021) Léna Royston et al. Immunity Inflammation and Disease
- Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
- (2021) Robin K Avery et al. CLINICAL INFECTIOUS DISEASES
- Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study
- (2020) Phaedon Zavras et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
- (2020) Hermann Einsele et al. BLOOD
- Clinical “real‐world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients
- (2020) Anthony Anderson et al. CLINICAL TRANSPLANTATION
- Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation
- (2020) Jiaqi Fang et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant
- (2020) Joyce J. Johnsrud et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection
- (2020) Sunwen Chou et al. JOURNAL OF INFECTIOUS DISEASES
- Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxis
- (2020) A. Lin et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cost‐effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective
- (2020) Adnan Alsumali et al. JOURNAL OF MEDICAL VIROLOGY
- Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a “Safe Corridor” after kidney transplantation?
- (2020) Guy El Helou et al. Transplant Infectious Disease
- Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection
- (2020) Irene Cassaniti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature
- (2020) Eveline Hofmann et al. Transplant Infectious Disease
- Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
- (2019) Raymund R. Razonable et al. CLINICAL TRANSPLANTATION
- A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients
- (2019) Deepali Kumar et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
- (2019) Susanne Jung et al. BMC INFECTIOUS DISEASES
- Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands
- (2019) Coretta C Van Leer Buter et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
- (2019) Per Ljungman et al. LANCET INFECTIOUS DISEASES
- Incidence and risk factors associated with cytomegalovirus infection after thetreatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy
- (2019) Claudia Felipe et al. Transplant Infectious Disease
- Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
- (2019) Mark P Khurana et al. Open Forum Infectious Diseases
- A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation
- (2019) Per Ljungman et al. CLINICAL INFECTIOUS DISEASES
- Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation
- (2019) Fareed Khawaja et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Clinical and economic burden of pre‐emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients
- (2019) Lynn El Haddad et al. JOURNAL OF MEDICAL VIROLOGY
- Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation
- (2019) Johan Maertens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients
- (2019) Cameron M Douglas et al. JOURNAL OF INFECTIOUS DISEASES
- Estudio de resistencias de citomegalovirus en pacientes receptores de trasplante alogénico de progenitores hematopoyéticos
- (2019) Alba Guiu et al. MEDICINA CLINICA
- Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
- (2019) Francisco M. Marty et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection
- (2019) Sunwen Chou et al. ANTIVIRAL RESEARCH
- The Development of Therapeutics for the Treatment and Prevention of CMV Disease in the Transplant Population: A Regulatory Perspective
- (2019) Aimee C Hodowanec et al. JOURNAL OF INFECTIOUS DISEASES
- Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence
- (2019) Ghady Haidar et al. JOURNAL OF INFECTIOUS DISEASES
- A New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by in vitro Exposure to Letermovir and Ganciclovir
- (2018) Sunwen Chou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus
- (2018) Sunwen Chou et al. ANTIVIRAL RESEARCH
- Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients
- (2018) Seong Jin Kim et al. Transplant Infectious Disease
- The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
- (2018) Camille N. Kotton et al. TRANSPLANTATION
- Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
- (2018) Roy F Chemaly et al. CLINICAL INFECTIOUS DISEASES
- Absolute Lymphocyte Count Thresholds: A Simple Readily Available Tool to Predict the Risk of Cytomegalovirus Infection after Transplantation
- (2018) Atibordee Meesing et al. Open Forum Infectious Diseases
- Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis
- (2018) Bettina M. Knoll et al. BONE MARROW TRANSPLANTATION
- Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
- (2018) Genovefa A Papanicolaou et al. CLINICAL INFECTIOUS DISEASES
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
- (2017) Francisco M. Marty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
- (2016) P. Teira et al. BLOOD
- Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection
- (2016) Robin K. Avery et al. TRANSPLANTATION
- Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
- (2016) Margaret L Green et al. Lancet Haematology
- RapidIn VitroEvolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance
- (2015) Sunwen Chou ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)
- (2015) Peter Lischka et al. JOURNAL OF INFECTIOUS DISEASES
- Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
- (2014) Roy F. Chemaly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review
- (2013) Ella J. Ariza-Heredia et al. CANCER LETTERS
- Why did maribavir fail in stem-cell transplants?
- (2011) David R Snydman LANCET INFECTIOUS DISEASES
- Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
- (2011) Francisco M Marty et al. LANCET INFECTIOUS DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started